Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06546020 · ClinicalTrials.gov registry record · NA
Gut Microbiota-dependent Health Impacts of Haskap Berries
A NA study of Inflammation and Metabolic Disease, sponsored by Montana State University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06546020: Recruiting NA study of Inflammation and Metabolic Disease, sponsored by Montana State University.
NCT06546020 is a NA study of Inflammation and Metabolic Disease that is actively recruiting participants, run by Montana State University. The registered enrollment target is 120 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06546020, a NA study of Inflammation and Metabolic Disease, is actively recruiting participants, sponsored by Montana State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Polyphenol-rich Haskap berries (Haskap) have untapped therapeutic potential to improve human health, and agricultural producers in northern U.S. states are poised to increase production if consumer demand increases. A critical knowledge gap is that little is known about the interactions between gut microbes and Haskap polyphenols to produce bioactive metabolites linked to downstream health impacts. Additionally, little is known about which Haskap varieties and harvest timing yield the greatest bioactive potential. This study aims to address these gaps by investigating the interaction of bioactive components in Haskap with gut microbiota and the resultant gut and serum metabolites, inflammation, and metabolic health, and then couple this with analysis of berries from different Haskap varieties and harvest times.
Primary Outcome
fecal microbial composition
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Haskap berry smoothie
- DIETARY_SUPPLEMENT Placebo comparator
Study Locations (1)
Montana
- Montana State University - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2028-05 |
| Phase | NA |
What NCT06546020 shows while recruiting
NCT06546020 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (58% lower).
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Haskap berry smoothie is the first listed.
NCT06546020 reports a single indexed study location in Montana.
Frequently Asked Questions
What is clinical trial NCT06546020 about?
NCT06546020 is a clinical study titled "Gut Microbiota-dependent Health Impacts of Haskap Berries". Polyphenol-rich Haskap berries (Haskap) have untapped therapeutic potential to improve human health, and agricultural producers in northern U.S. states are poised to increase production if consumer demand increases. A critical knowledge gap is that little is known about the interactions between gut ...
What is the current status of trial NCT06546020?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-02-26. Estimated completion is 2028-05.
What conditions does trial NCT06546020 study?
This clinical trial studies the following conditions: Inflammation, Metabolic Disease, Microbial Colonization.
What interventions are being tested in trial NCT06546020?
The interventions under investigation include: Haskap berry smoothie (DIETARY_SUPPLEMENT), Placebo comparator (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06546020?
This trial is sponsored by Montana State University, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06546020 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06546020's enrollment target sits among peer trials
120 38th of 132 higher than 94 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Evaluating Whether Hyperbaric Oxygen Therapy Can Improve VO₂-Max and Reduce Inflammation Markers in Healthy Adults Ages 30-60.
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI